An interventional study of Personalized Cardiopulmonary Rehabilitation and Structured Pacing in Long COVID, Long Covid19 and Long Covid-19, sponsored by Duke University. Completed at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Duke University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.
Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 8th largest by enrollment of the 156 interventional ones that give a count, is one of 43 that started in 2024, is one of 78 with no phase, and was the 134th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–75
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 54 · Phase 3 13 · Phase 4 4
First in 2020; this study’s year is marked. 43 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 53 across the 156 interventional studies, 155 across the 37 observational. Of the 96 that completed or were terminated, 30 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 195 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 8 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
30 of the studies in Post-Acute COVID-19 Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06974084Phase 3HealthBio, Inc.A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | 2026-12-01 |
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
Add all 30 to your calendar (.ics) → With an account.
Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).
The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.
Study interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix. Study intervention appendices may be added or removed according to adaptive design and/or emerging evidence.
The platform protocol enrolls participants who meet study eligibility criteria. After completing initial screening assessments, eligible participants are assigned to one of the study intervention appendices that are actively enrolling. Participants must meet certain criteria within a specific appendix in order to be included in that appendix. Once assigned to an appendix, eligible participants are randomized to either the study intervention group or a control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization*
Suspected case of SARS-CoV-2 infection - Three options, A through C:
A. A person who meets the clinical OR epidemiological criteria. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization; or C. With no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.
Probable case of SARS-CoV-2 infection:
A. A patient who meets clinical criteria above AND is a contact of a probable or confirmed case or is linked to a COVID-19 cluster.
Confirmed case of SARS-CoV-2 infection - Two options, A and B:
A. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or B. Meeting clinical criteria AND/OR epidemiological criteria (See suspected case A above for criteria). With a positive professional use or self-test SARS- CoV-2 Antigen-Rapid Diagnostic Test.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Appendix A is a randomized controlled trial designed to evaluate the effect of a 12-week personalized cardiopulmonary rehabilitation intervention on exercise tolerance in participants with PASC. Participants who meet eligibility criteria for Appendix A will be assigned to either Personalized Cardiopulmonary Rehabilitation (study intervention group) or Education (control group) in a 1:1 ratio. The intervention duration is 12 weeks with a follow-up period of 3 months (total study duration of 6 months). Anticipated enrollment is 360 participants. Details about Appendix A: Cardiopulmonary Rehabilitation (Exercise Intolerance) are available under NCT06404060.
Behavioral: Personalized Cardiopulmonary Rehabilitation · Other: Education
Appendix B is a randomized controlled trial designed to evaluate the effect of a 12-week Structured Pacing intervention on reducing the symptoms of post-exertional malaise (PEM) in participants with PASC. Participants who meet eligibility criteria for Appendix B will be assigned to either Structured Pacing (study intervention group) or Usual Care (control group) in a 1:1 ratio. The intervention duration is 12 weeks with a follow-up period of 3 months (total study duration of 6 months). Anticipated enrollment is 300 participants. Details about Appendix B: Structured Pacing (PEM) are available under NCT06404073.
Behavioral: Structured Pacing · Other: Usual Care
Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation. Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training.
Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
Total Number of Participants Enrolled in Each Appendix
Total number of participants enrolled in each Appendix will be reported. Appendix-specific outcome measure data will be reported under the associated NCT ID.
Time frame: 6 months
This is a platform study record.
| Milestone | Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | Experimental: Appendix B - Structured Pacing (PEM) |
|---|---|---|
| Started | 360 | 300 |
| Completed | 360 | 300 |
| Not completed | 0 | 0 |
Total number of participants enrolled in each Appendix will be reported. Appendix-specific outcome measure data will be reported under the associated NCT ID.
| Participants | Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | Experimental: Appendix B - Structured Pacing (PEM) |
|---|---|---|
| Total Number of Participants Enrolled in Each Appendix | 360 | 300 |
Collected over Adverse Events were not collected during the screening period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | — | — | — |
| Experimental: Appendix B - Structured Pacing (PEM) | — | — | — |
This is a platform study record.
| Age, Continuous(years) | Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | Experimental: Appendix B - Structured Pacing (PEM) | Total |
|---|---|---|---|
| Median | 55.0 (40.6 to 63.2) | 50.4 (39.9 to 59.2) | 52.9 (40.2 to 61.7) |
| Sex: Female, Male(Participants) | Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | Experimental: Appendix B - Structured Pacing (PEM) | Total |
|---|---|---|---|
| Female | 266 | 225 | 491 |
| Male | 94 | 75 | 169 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | Experimental: Appendix B - Structured Pacing (PEM) | Total |
|---|---|---|---|
| Hispanic or Latino | 81 | 29 | 110 |
| Not Hispanic or Latino | 277 | 271 | 548 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | Experimental: Appendix B - Structured Pacing (PEM) | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 2 | 1 | 3 |
| Race — Asian | 11 | 5 | 16 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Race — Middle Eastern or North African | 1 | 1 | 2 |
| Race — Black or African American | 36 | 24 | 60 |
| Race — White | 291 | 252 | 543 |
| Race — More than one race | 9 | 9 | 18 |
| Race — Unknown or Not Reported | 9 | 7 | 16 |
| Region of Enrollment(Participants) | Experimental: Appendix A - Cardiopulmonary Rehabilitation (Exercise Intolerance) | Experimental: Appendix B - Structured Pacing (PEM) | Total |
|---|---|---|---|
| United States | 360 | 300 | 660 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The summary of the results will be shared on the study website: https://recovercovid.org/
Ran from Jul 2024 to primary completion in Oct 2025, 15 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 15 months is close to that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →